ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens

This study has been completed.
The University of New South Wales
Information provided by (Responsible Party):
Kirby Institute Identifier:
First received: June 8, 2006
Last updated: April 17, 2012
Last verified: April 2012
Results First Received: April 17, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)
Drug: Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
Drug: Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
TDF/FTC+EFV No text entered.
TDF/FTC+r/ATV Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
TDF/FTC+AZT+ABC Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
Total Total of all reporting groups

Baseline Measures
    TDF/FTC+EFV     TDF/FTC+r/ATV     TDF/FTC+AZT+ABC     Total  
Number of Participants  
[units: participants]
  115     107     105     327  
[units: participants]
<=18 years     0     0     0     0  
Between 18 and 65 years     115     107     105     327  
>=65 years     0     0     0     0  
[units: participants]
Female     24     30     22     76  
Male     91     77     83     251  
Race (NIH/OMB)  
[units: participants]
American Indian or Alaska Native     0     0     0     0  
Asian     35     37     35     107  
Native Hawaiian or Other Pacific Islander     0     0     0     0  
Black or African American     10     7     10     27  
White     46     43     35     124  
More than one race     24     20     25     69  
Unknown or Not Reported     0     0     0     0  

  Outcome Measures

1.  Primary:   Time-weighted Mean Change From Baseline Plasma HIV-RNA.   [ Time Frame: 48 weeks ]

2.  Secondary:   Compare the Safety of Three Strategic Regimens of Initial ART Containing a Fixed Dose Formulation of Tenofovir and Emtricitabine, With Either Efavirenz or Ritonavir Boosted Atazanavir or Zidovudine Plus Abacavir.   [ Time Frame: 144 weeks ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   Yes

  Serious Adverse Events

  Other Adverse Events

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Inadequate sample size for true comparison of non-inferiority  

Results Point of Contact:  
Name/Title: Sean Emery
Organization: Kirby Institute
phone: 9385 0900

Publications of Results:

Responsible Party: Kirby Institute Identifier: NCT00335322     History of Changes
Other Study ID Numbers: NCHECR-ALTAIR
Study First Received: June 8, 2006
Results First Received: April 17, 2012
Last Updated: April 17, 2012
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration